Breaking News

SGD Pharma Invests $21.7M to Upgrade Zhanjiang Plant

Investment includes a complete rebuild of the plant’s furnace and improvement of the plant’s facilities.

SGD Pharma, a global provider of primary glass packaging for pharmaceutical and cosmetic products, has invested more than €20 million ($21.7 million) to upgrade its Zhanjiang plant in China, including a complete rebuild of its furnace and comprehensive improvement of the plant’s facilities.
 
Using advanced design and technologies, this new furnace allows the Zhanjiang plant to increase capacity, improve energy performance and minimize energy consumption, reducing the Group’s carbon footprint in line with its environmental commitments and long-term decarbonization roadmap. SGD Pharma’s objective is to reduce CO2 emissions from 2020 by 35% in 2030 and by 65% in 2040.
 
Alongside the furnace rebuild, production lines and inspection equipment at the plant have been upgraded to improve glass quality and production flexibility. The plant now offers feeder coloration and a range of colored glass options to meet specific requirements, mainly for luxury beauty products.
 
Chunyan Zheng, Deputy General Manager at SGD Pharma Zhanjiang plant, said: “This significant investment allows us to improve the operational excellence of Zhanjiang plant making sure that we manufacture the best in quality to serve our customers worldwide. We are delighted with the improvements to our plant and are excited about the new features that we can now provide our customers.”
 
Frédéric Barbier, General Manager of SGD Pharma BU APAC, added: “SGD Pharma has been working with the Science Based Targets initiative (SBTi) on the reduction of CO2 emissions and has developed a 1.5°C decarbonization pathway and target validation. The Zhanjiang plant is a critical part of this ambitious decarbonization plan. It is fantastic to see our new furnace working in a way that helps us to not only increase productivity but also minimize environmental impact. This €20 million renovation project illustrates our sustained investment strategy, and ongoing commitment towards a more sustainable future.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters